HDAC9 and uveal melanoma: Pan-HDAC inhibitors potentiate the cytotoxic effect of MEKi in human PDAC, uveal melanoma and CRC cells 98-100, and one possible mechanism is that HDAC inhibitors attenuate treatment-induced upregulation of pAKT and YAP1 100.